Table 2.
Serum levels of TNF, IFX/ADM and ADA according to the FCGR3 V158F polymorphism
| TNF | n | IFX | n | ADM | ADAs | anti-TNF intensification | ||
|---|---|---|---|---|---|---|---|---|
| (pg/mL±SD) (ln) | (µg/mL±SD) | (µg/mL±SD) | No. (%) | No. % | ||||
| V158F FCGR3A | FF (n=40) | 5.42±1.37 | 21 | 2.37±1.92 | 19 | 6.28±3.79 | 2 (5) | 9 (22.5) |
| FV (n=47) | 5.09±1.28 | 33 | 3.45±3.91 | 14 | 5.01±3.81 | 5 (10.6) | 15 (31.9) | |
| VV (n=16) | 4.93±1.17 | 12 | 1.76±1.67 | 4 | 3.37± 3.52 | 6 (37.5) | 9 (56.3) | |
| p value | 0.098 | 0.2 | 0.58 | 0.004 | 0.03 |
IFX: infliximab, ADA: adalimmab, SD: Standard deviation, ADA: Anti-drug antibody